This report is based on data from 800 pharma and biopharma professionals at director-level and above. These professionals came from 18 countries, with 26% holding C-suite/board-level roles and 30% from organizations with annual revenues of more than $1 billion. We also conducted several in-depth interviews with industry experts to find out how biopharma companies are prioritizing sustainability and delve into what progress has already been made.
